{"schema_version":"secwatch.filing_event.v1","accession":"0001062822-24-000054","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2024-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.540672+00:00","generated_at":"2026-05-30T13:34:20.788365+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lexicon licenses sotagliflozin ex-US/Europe to Viatris for $25M upfront plus milestones","bullets":["Exclusive license to Viatris for sotagliflozin development and commercialization outside US and Europe.","Viatris pays $25M upfront; Lexicon eligible for up to $12M regulatory and $185M sales milestones.","Tiered royalties: low double-digit to upper-teens percentages of net sales in licensed territory.","Lexicon to supply drug under a separate manufacturing and supply agreement with Viatris.","Viatris responsible for regulatory approvals, commercialization, and any additional clinical trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001062822-24-000054","json":"https://secwatch.observer/filing/0001062822-24-000054.json","markdown":"https://secwatch.observer/filing/0001062822-24-000054.md","text":"https://secwatch.observer/filing/0001062822-24-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000106282224000054/0001062822-24-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000106282224000054/lxrx-20241016.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T13:34:20.788365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}